45 citations,
February 2018 in “Journal of basic and clinical physiology and pharmacology/Journal of basic & clinical physiology & pharmacology” *Acorus calamus* has many medicinal benefits but needs more safety research.
45 citations,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
44 citations,
April 2012 in “American Journal of Clinical Dermatology” Scarring alopecias are complex hair loss disorders that require early treatment to prevent permanent hair loss.
44 citations,
November 2011 in “The Journal of Dermatology” New understanding of the causes of primary cicatricial alopecia has led to better diagnosis and potential new treatments.
44 citations,
January 2002 in “American Journal of Clinical Dermatology” Skin reactions to antidepressants are common but usually not serious and can be treated.
43 citations,
December 2008 in “PLOS ONE” Medical terms make new health issues seem more serious but don't affect views on well-known conditions.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
42 citations,
December 2016 in “Cell Death & Differentiation” Damaging mitochondrial DNA in mice speeds up aging due to increased reactive oxygen species, not through the p53/p21 pathway.
42 citations,
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.
41 citations,
December 2018 in “Experimental Dermatology” Understanding how melanocyte stem cells work could lead to new treatments for hair graying and skin pigmentation disorders.